ANDROMEDA-SHOCK-2 is a worldwide RCT testing the superiority of a CRT-targeted, hemodynamic phenotype-based resuscitation over usual care in early septic shock!
Hello A2 Family!
A lot of good information about A2, great hemodynamic info, and online classes for free? YES!
Check it out on our website :
https://t.co/HT3QcE5T1x
(1/x) With the publication of Andromeda-Shock 2 in JAMA there has been a lot of excitement, and rightly so, a lot of questions and skepticism.
The main criticism I've heard is: "there is mainly a reduction in organ support, not mortality, is that even patient important?"
I think it is! 👇
AS-2 debate is an opportunity to share this excellent article @AndromedaShock@edu_kattan
Let’s think about macro and microcirculartory (un)coupling in our medical practice.
And try to avoid over-resuscitation :)
https://t.co/4hG5rvlneS
@PatientStormDoc@icmteaching I think the folks that got hung-up on the hierarchical endpoint of ANDROMEDA-SHOCK2 badly missed the target.
It was a great call - need more of it.
Much better to learn something, then debate/discuss its significance & application than it is to learn nothing at all.
Physical exam and capillary refill for the win!
Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock https://t.co/SdMpZ1UwW3
Super stoked about this. The interface paper is in preprint while awaiting final reviews! I truly think the concepts here are how resuscitation will take place in a few years . https://t.co/8G2NvCnECi ping @EMNerd_@khaycock2@SaraCrager@ShockAndromeda2@msiuba@icmteaching
Writing ANDROMEDA-SHOCK-2 draft with the great Eduardo Kattan on a cold Holiday morning at the University. Empty Streets. Blues on the background. Pretty excited by the results that we cannot tell yet jajaja. In contact with Jan Bakker, Gustavo Ospina , Alex Cavalcanti💪💪😎🍷
Can pulse pressure estimate stroke volume? Often. But context is everything .
Many pitfalls (see 👇).
🧠 New @CriticalCareJ review by @edu_kattan & @AndromedaShock
📊 ANDROMEDA-PEGASUS is coming and and may help us get it right.
🔗 https://t.co/tmp5QahqBD
37 centers have already been activated in the great ANDROMEDA- PEGASUS Study. A 30min operational video briefly explaning background and methodological aspects. Still possible to be included💪>200 centers in 38 countries, 4 continents expected https://t.co/Lw6wNPUdhq
First patient recruited in the e-Prone trial in Mexico!! PROLONGED prone positioning in ARDS seems to have helped some patients during the pandemic, but does it really work? Care to join us to the major RCT putting it to test??? (NCT06854627). Contact @eprone_study. Please share!
Everybody is invited to the free Webinar (in Spanish) to celebrate 10 years of LIVEN! Our investigator-generated research Network! The issue “Hot Topics in LA’s Research” Not to be missed! https://t.co/fHO5FMVrBD
ANDROMEDA-PEGASUS started recruitment today in Budapest and Montreal! A big cross-sectional study focused on the RR between pulse pressure and stroke volume in diverse clinical settings and static/dynamic situations. Sum
of 37 countries, 4 continents, >200 centers, >2000 pts 💪
A new addition to the ANDROMEDA-SHOCK family: PEGASUS! Providing an epidemiological perspective to the RR between pulse pressure and stroke volume! Fundamental study after A2! Cross-talk now between Physiology and Epidemiology!! NCT 06737614
🎉 The ANDROMEDA-SHOCK 2 trial has officially reached its 1,500 patients target!
🙏 Our deepest gratitude to every patient, clinician, researcher involved.
Stay tuned — the future of sepsis care is being shaped!
#AndromedaShock2#Sepsis#CriticalCare#RCT